16 citations
,
March 2017 in “Journal of inclusion phenomena and macrocyclic chemistry” This study found that using 2-hydroxypropyl-ß-cyclodextrin (HP-ß-CD) to encapsulate minoxidil can create a stable aqueous solution, potentially replacing the need for organic solvents in topical treatments for androgenic alopecia.
18 citations
,
March 2014 in “Drug Development and Industrial Pharmacy” This study evaluated new aqueous gel formulations of minoxidil without irritants and found that the calcium alginate gel showed the best performance in terms of drug release and skin permeation.
100 citations
,
April 2010 in “Expert Opinion on Pharmacotherapy” This article reviews existing treatments for male-pattern hair loss, noting that while they can slow progression, they generally achieve only partial hair regrowth.
39 citations
,
April 2010 in “International Journal of Pharmaceutics” This study found that using monoolein cubic phase nanoparticles with an entrapped hydroxypropyl β-cyclodextrin/minoxidil complex increased minoxidil skin permeation, but minoxidil retention in the skin was higher with a traditional solution.
28 citations
,
April 2008 in “Journal of Inclusion Phenomena and Macrocyclic Chemistry” This study identified a weak interaction between minoxidil and ß-cyclodextrin in solution, forming an inclusion complex with a 1:1 molar ratio.
397 citations
,
February 2004 in “British Journal of Dermatology” This article reviews the mechanisms by which minoxidil stimulates hair growth and reports no new clinical findings.
24 citations
,
January 2003 in “Drug Delivery” This study found that only minoxidil encapsulated in cationic vesicles significantly promoted hair growth in mice, likely due to its higher retention on the skin.
174 citations
,
November 2002 in “Expert Reviews in Molecular Medicine” This review discusses the genetic factors contributing to androgenetic alopecia and highlights the potential for developing more effective therapies based on recent discoveries, but reports no new clinical results.
269 citations
,
August 2002 in “Journal of The American Academy of Dermatology” This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.
123 citations
,
February 2002 in “Journal of The American Academy of Dermatology” Minoxidil can cause skin allergy; use alternative solvents or treatments if allergic.
184 citations
,
January 2000 in “European Urology” This abstract reviews the role of finasteride and potential dual 5alpha-reductase inhibitors in treating benign prostatic hyperplasia, suggesting that dual inhibitors may offer greater DHT suppression and therapeutic advantages, while emphasizing the need for clinical evaluation.
59 citations
,
August 1998 in “International Journal of Dermatology” Genetics and hormones cause hair loss; finasteride treats it safely.
33 citations
,
June 1995 in “Journal of Pharmaceutical Sciences” This study found that minoxidil penetration through the skin increased with higher ethanol content and occlusion, with the highest penetration observed at 90% ethanol.
